Health welcomes arrival of Lenacapavir in South Africa
This image was generated by AI and may not depict real events.
The Department of Health in South Africa has welcomed the arrival of the first batch of Lenacapavir, a new HIV prevention medicine. This six-monthly injectable is expected to expand HIV prevention choices and improve adherence, especially among vulnerable groups.
The Department of Health has received 37,920 doses of Lenacapavir, a new HIV prevention medicine. This medicine is part of the country's efforts to reduce new HIV infections by 2030. Lenacapavir is a six-monthly injectable that will expand HIV prevention choices. It is expected to improve adherence, especially among adolescent girls, young women, sex workers, and men having sex with men. The Department will announce the official launch and phased implementation plan in the coming weeks. The Minister of Health is excited about this development, which is considered one of the most exciting HIV prevention advances in years.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.